See more : Littlefield Corporation (LTFD) Income Statement Analysis – Financial Results
Complete financial analysis of Acrivon Therapeutics, Inc. Common Stock (ACRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acrivon Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Concejo AB (publ) (CNCJO-B.ST) Income Statement Analysis – Financial Results
- Tri-Continental Corporation PFD $2.50 (TY-P) Income Statement Analysis – Financial Results
- DFI Retail Group Holdings Limited (DFIHY) Income Statement Analysis – Financial Results
- Orla Mining Ltd. (ORLA) Income Statement Analysis – Financial Results
- WANdisco plc (WAND.L) Income Statement Analysis – Financial Results
Acrivon Therapeutics, Inc. Common Stock (ACRV)
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 536.00K | 1.10M | 832.00K | 13.00K |
| Gross Profit | -536.00K | -1.10M | -832.00K | -13.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.49M | 23.95M | 13.72M | 1.87M |
| General & Administrative | 21.08M | 8.71M | 2.47M | 1.30M |
| Selling & Marketing | 134.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.21M | 8.71M | 2.47M | 1.30M |
| Other Expenses | 0.00 | 1.49M | -59.00K | -2.14M |
| Operating Expenses | 66.70M | 32.66M | 16.18M | 3.17M |
| Cost & Expenses | 67.24M | 32.66M | 16.18M | 3.17M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 536.00K | 1.10M | 832.00K | 13.00K |
| EBITDA | -59.85M | -30.07M | -15.41M | -5.29M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -67.24M | -32.66M | -16.18M | -3.17M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.85M | 1.49M | -59.00K | -2.14M |
| Income Before Tax | -60.39M | -31.17M | -16.24M | -5.31M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.49M | -199.56K | -193.30K |
| Net Income | -60.39M | -29.68M | -16.24M | -5.31M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.74 | -1.35 | -0.78 | -0.25 |
| EPS Diluted | -2.74 | -1.35 | -0.78 | -0.25 |
| Weighted Avg Shares Out | 22.08M | 21.92M | 20.86M | 20.86M |
| Weighted Avg Shares Out (Dil) | 22.08M | 21.92M | 20.86M | 20.86M |
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
Source: https://incomestatements.info
Category: Stock Reports